Identification
- Summary
Gadopentetic acid is a gadolinium compound used as a contrast agent in MRIs.
- Brand Names
- Magnevist
- Generic Name
- Gadopentetic acid
- DrugBank Accession Number
- DB00789
- Background
A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Gadopentetic acid (DB00789)
- Weight
- Average: 547.58
Monoisotopic: 548.03898 - Chemical Formula
- C14H20GdN3O10
- Synonyms
- Acide gadopentetique
- ácido gadopentético
- Acidum gadopenteticum
- Gadolinium diethylenetriamine pentaacetic acid
- Gadolinium DTPA
- Gadopentetate
- Gadopentetic acid
- External IDs
- SH L 451 A
- SH-L-451-A
- SHL-451A
Pharmacology
- Indication
For use with magnetic resonance imaging (MRI) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues as well as lesions with abnormal vascularity in the head and neck. Also used to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. MR images are based primarily on proton density and proton relaxation dynamics. MR instruments are sensitive to two different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and T2 (spin-spin or transverse relaxation time). Paramagnetic agents contain one or more unpaired electrons that enhance the T1 and T2 relaxation rates of protons in their molecular environment. The proton relaxation effect (PRE) of an unpaired electron is 700 times stronger than that of a proton itself. In MRI, visualization of normal and pathological brain tissue depends in part on variations in the radio frequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadopentetate dimeglumine shortens the T1 and T2 relaxation times in tissues where it accumulates. In the central nervous system (CNS), gadopentetate dimeglumine enhances visualization of normal tissues that lack a blood-brain barrier, such as the pituitary gland and the meninges. Gadopentetate dimeglumine does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in CNS lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadopentetate dimeglumine in lesions such as neoplasms, abscesses, and subacute infarcts. Outside the CNS, gadopentetate dimeglumine rapidly reaches equilibrium in the interstitial compartment and enhances signal in all tissues as a function of delivery and size of the interstitial compartment. This compound has also been found to inhibit human erythrocyte 6-phosphogluconate dehydrogenase.
Target Actions Organism U6-phosphogluconate dehydrogenase, decarboxylating inhibitorHumans - Absorption
Not Available
- Volume of distribution
- 266 ± 43 mL/kg
- Protein binding
Not Available
- Metabolism
No detectable biotransformation or decomposition.
- Route of elimination
Gadopentetate is exclusively eliminated in the urine with 83 ± 14% (mean ± SD) of the dose excreted within 6 hours and 91 ± 13% (mean ± SD) by 24 hours, post-injection.
- Half-life
Distribution half life 12 minutes, elimination half 100 minutes
- Clearance
- 1.94 +/- 0.28 mL/min/kg [Normal subjects]
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Gadopentetic acid may decrease the excretion rate of Abacavir which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Gadopentetic acid which could result in a lower serum level and potentially a reduction in efficacy. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Gadopentetate dimeglumine RH248G8V27 86050-77-3 LGMLJQFQKXPRGA-VPVMAENOSA-K - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Gadopentetate Dimeglumine Injection Solution 469 mg / mL Intravenous Avir Pharma Inc. Not applicable Not applicable Canada 
Gadopentetate Dimeglumine Injection, USP Solution 469 mg / mL Intravenous Jubilant Draximage Inc. Dba Jubilant Radiopharma Not applicable Not applicable Canada Magnevist Injection 469.01 mg/1mL Intravenous Bayer HealthCare Pharmaceuticals Inc. 2014-06-11 2023-01-31 US 
Magnevist Solution 469 mg / mL Intravenous Bayer 1992-12-31 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Gadopentetate dimeglumine Injection 469.01 mg/1mL Intravenous Alvogen, Inc 2014-02-24 2020-01-16 US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image MAGNEVIST 10ML Injection, solution 469 mg/ml Intravenous BAYER CO. (MALAYSIA) SDN. BHD. 2017-02-04 2018-08-31 Malaysia 
MAGNEVIST INJECTION 100ML Injection 469 mg/ml Intravenous BAYER CO. (MALAYSIA) SDN. BHD. 2013-08-24 2018-08-31 Malaysia MAGNEVIST INJECTION 30ML Injection, solution 469 mg/ml Intravenous BAYER CO. (MALAYSIA) SDN. BHD. 2013-08-24 2018-08-31 Malaysia
Categories
- ATC Codes
- V08CA01 — Gadopentetic acid
- Drug Categories
- Acetates
- Acids, Acyclic
- Amines
- Compounds used in a research, industrial, or household setting
- Contrast Media
- Coordination Complexes
- Diagnostic Uses of Chemicals
- Drugs that are Mainly Renally Excreted
- Magnetic Resonance Contrast Activity
- Magnetic Resonance Imaging Contrast Media
- Miscellaneous Therapeutic Agents
- Other Diagnostics
- Paramagnetic Contrast Agent
- Paramagnetic Contrast Media
- Polyamines
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- K2I13DR72L
- CAS number
- 80529-93-7
- InChI Key
- IZOOGPBRAOKZFK-UHFFFAOYSA-K
- InChI
- InChI=1S/C14H23N3O10.Gd/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);/q;+3/p-3
- IUPAC Name
- gadolinium(3+) 2-[bis({2-[bis(carboxymethyl)amino]ethyl})amino]acetate
- SMILES
- [Gd+3].OC(=O)CN(CCN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O)CC([O-])=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014927
- PubChem Compound
- 55466
- PubChem Substance
- 46504878
- ChemSpider
- 138549
- 1546432
- ChEBI
- 35778
- ChEMBL
- CHEMBL1200431
- PharmGKB
- PA164748760
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Gadopentetic_acid
- FDA label
- Download (102 KB)
- MSDS
- Download (42.2 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Diagnostic Acute Graft Rejection / Cardiac Transplant / Chronic Graft Rejection 1 4 Completed Diagnostic Brain Neoplasm 1 4 Completed Treatment Disorder of Shoulder 1 4 Unknown Status Diagnostic Breast Cancer Diagnosis / Magnetic Resonance Imaging (MRI) / Positron Emission Tomography 1 3 Completed Diagnostic Anatomic renal artery stenosis 1
Pharmacoeconomics
- Manufacturers
- Bayer healthcare pharmaceuticals inc
- Packagers
- Bayer Healthcare
- Dosage Forms
Form Route Strength Solution Intravenous 10 ml Solution Intravenous 15 ml Solution Intravenous 20 ml Injection, solution Injection Intravenous Injection Intravenous 469.01 mg/1mL Injection, solution Intra-articular 37.6 MG/20ML Injection, solution Intra-articular 469 MG/ML Injection, solution Intra-articular; Intravenous 469 MG/ML Solution Intravenous 469 mg/1ml Solution Intravenous 469 mg / mL Injection, solution Intra-articular 2 mmol/l Injection, solution Intravenous 469 mg/ml Solution Rectal Solution Intravenous 0.5 mmol/ml Solution Intravenous Injection Intravenous 469 mg/ml Solution Intravenous 469.01 mg Injection, solution 469 MG/ML Solution Intravenous 529 mg Solution Oral - Prices
Unit description Cost Unit Magnevist vial 5.54USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5560903 No 1996-10-01 2013-10-01 US US5362475 No 1994-11-08 2011-11-08 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 7.86 mg/mL ALOGPS logP 0.05 ALOGPS logP -6.3 Chemaxon logS -1.9 ALOGPS pKa (Strongest Acidic) 1.95 Chemaxon pKa (Strongest Basic) 8.82 Chemaxon Physiological Charge -3 Chemaxon Hydrogen Acceptor Count 13 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 204.71 Å2 Chemaxon Rotatable Bond Count 16 Chemaxon Refractivity 118.96 m3·mol-1 Chemaxon Polarizability 35.24 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.9896 Blood Brain Barrier - 0.9154 Caco-2 permeable - 0.652 P-glycoprotein substrate Substrate 0.7451 P-glycoprotein inhibitor I Non-inhibitor 0.8839 P-glycoprotein inhibitor II Non-inhibitor 0.8277 Renal organic cation transporter Non-inhibitor 0.9191 CYP450 2C9 substrate Non-substrate 0.8788 CYP450 2D6 substrate Non-substrate 0.8015 CYP450 3A4 substrate Non-substrate 0.644 CYP450 1A2 substrate Non-inhibitor 0.8494 CYP450 2C9 inhibitor Non-inhibitor 0.8624 CYP450 2D6 inhibitor Non-inhibitor 0.925 CYP450 2C19 inhibitor Non-inhibitor 0.8775 CYP450 3A4 inhibitor Non-inhibitor 0.9468 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9956 Ames test Non AMES toxic 0.7974 Carcinogenicity Non-carcinogens 0.8588 Biodegradation Ready biodegradable 0.5775 Rat acute toxicity 2.2141 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7992 hERG inhibition (predictor II) Non-inhibitor 0.819
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Phosphogluconate dehydrogenase (decarboxylating) activity
- Specific Function
- Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH.
- Gene Name
- PGD
- Uniprot ID
- P52209
- Uniprot Name
- 6-phosphogluconate dehydrogenase, decarboxylating
- Molecular Weight
- 53139.56 Da
References
- Akkemik E, Budak H, Ciftci M: Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study. J Enzyme Inhib Med Chem. 2010 Aug;25(4):476-9. doi: 10.3109/14756360903257900. [Article]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55